目的 研究波棱甲素纳米混悬剂(PEDX-NS)的体内外抗乙肝病毒活性。方法 本实验选择HepG2 2.2.15细胞系和鸭乙肝病毒感染模型两种模型评价波棱甲素纳米混悬剂的体内外抗乙肝病毒活性,并与波棱甲素普通混悬剂(PEDX-CS)进行比较。结果 体外实验结果显示,波棱甲素纳米混悬剂可有效抑制2.2.15细胞抗原(HBsAg和HBeAg)的分泌,并呈现一定的剂量依赖性,且波棱甲素纳米混悬剂的抑制作用显著高于波棱甲素普通混悬剂(P<0.05或P<0.01)。体内实验结果显示,高、中剂量(100、60 mg·kg-1) 波棱甲素纳米混悬剂可显著降低鸭血清乙肝病毒-DNA的水平(P<0.05或P<0.01),且效果优于同剂量的波棱甲素普通混悬剂(P<0.05或P<0.01)。结论 结果表明,波棱甲素纳米混悬剂体内外均具有抗乙肝病毒活性,且抗病毒作用明显优于波棱甲素普通混悬剂,其机制可能在于将其制成纳米混悬剂之后,粒径减小,表面积增大,体内吸收增加,从而使它的药效作用增强。
Abstract
OBJECTIVE To evaluate the anti-hepatitis B virus (HBV) activity of herpetrione nanosuspension (PEDX-NS) both in vitro and in vivo. METHODS HepG2 2.2.15 cells and duck hepatitis B virus (DHBV) infected ducks as in vitro and in vivo models were used to compare the anti-HBV activity of PEDX-NS and PEDX coarse suspension (PEDX-CS). RESULTS In the HepG2 2.2.15 cell, PEDX-NS effectively suppressed the secretion of the HBV antigens (HBsAg and HBeAg) in a dose-dependent manner with significant difference from PEDX-CS (P<0.05 or P<0.01). In the in vivo evaluation, PEDX-NS with high dose (100 mg·kg-1) and middle dose (60 mg·kg-1) significantly reduced the serum HBV DNA level (P<0.05 or P<0.01) and the effect was better than that of PEDX-CS (P<0.05 or P<0.01). CONCLUSION The result revealed that PEDX-NS exhibits anti-HBV activity both in vitro and in vivo and its effect was superior to that of PEDX-CS. The mechanism is probably that the small particle size of PEDX-NS provides a large specific surface area that resulted in better absorption in vivo, thus enhancing its anti-HBV activity.
关键词
波棱甲素 /
纳米混悬剂 /
乙肝病毒 /
体内外评价
{{custom_keyword}} /
Key words
herpetrione /
nanosuspension /
hepatitis B virus /
in vitro and in vivo evaluation
{{custom_keyword}} /
中图分类号:
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LI L Y, DEJI L M, WEI Y F, et al. Literature data investigation in semem of Herpetospermum pedunculosum[J].China J Chin Mater Med(中国中药杂志),2005,30(12):893-895.
[2] CONG L B, W Q, LI X Y, et al. The study on the anti-hepatitis therapeutic basis of Herpetospermum caudigerum [J].J Med Res(医学研究杂志), 2007, 36(8): 75-76.
[3] YUAN H L, YANG M, LI X Y, et al. Hepatitis B virus inhibiting constituents from Herpetospermum caudigerum[J]. Chem Pharm Bull, 2006,54(11):1592-1594.
[4] YUAN H L, GUO J J, LI X Y, et al. Preparation and application of herperione and its capsule: China, 201110072191.9[P]. 2011-03-24.
[5] GUO J J,LI X Y, YUAN H L, et al. Preparation and dissolution determination of herpetrione nanosuspensions capsule [J].Chin Tradit Herb Drugs(中草药), 2012, 43(3):467-470.
[6] GUO J J, LI X Y, YUAN H L, et al. Preparation of herpetrione nanosuspensions and preliminary study on its pharmacokinetics[J].Chin Pharm J(中国药学杂志), 2012, 47(24):2004-2007.
[7] GUO J J, YUE P F, LV J L, et al. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension [J]. Int J Pharm, 2013,441(1-2):227.
[8] LV J L, LI X Y, YUAN H L, et al. Protective effect of herpetrione nanosuspension against acute liver injury induced by D-galactosamine in mice[J]. Chin Pharm J(中国药学杂志), 2011,46(24):1898-1901.
[9] SHEN B,JIN S,LV Q, et al. Enhanced intestinal absorption activity and hepatoprotective effect of herpetrione via preparation of nanosuspensions using pH-dependent dissolving-precipitating/homogenization process [J]. J Pharm Pharmacol, 2013,65(9):1382.
[10] LIU X Y, LI C P, WANG K X. Experimental study on polysaccharide of Cipangopaludina chinensis against HBV in vitro [J]. China J Chin Mater Med(中国中药杂志), 2013,38(6):879-883.
[11] ZUO Q Y, TAO L Q, LUO X, et al. Polysaccharide isolated from yulangsan inhibits duck hepatitis B virus and protects hepatocytes [J].China J Exp Tradit Med Form (中国实验方剂学杂志), 2013, 19(22):222-226.
[12] YANG K, JIA L, WEI S S, et al. Experimental study on Gan Tai capsule against HBV [J]. Chin Tradit Paten Med(中成药), 2011, 33(11):1969-1972.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家新药创制重大专项资助项目(2015ZX09101025);北京市科委重点资助项目(Z14110700220000)
{{custom_fund}}